Yıl: 2020 Cilt: 9 Sayı: 2 Sayfa Aralığı: 496 - 502 Metin Dili: İngilizce DOI: 10.5455/medscience.2020.09.9254 İndeks Tarihi: 29-10-2020

Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance

Öz:
The aim of this study is to determine the correlation of histopathological subtype with frozen section examination and the importance of immunohistochemical analysis ofovarian malignancies which also include metastatic ones. This study is a retrospective study that have included 55 patients who have been operated for adnexial tumor andhave the diagnosis of malignancy during surgery by frozen section or after surgery by final pathologic examination done by immunohistochemistry (IHC). The mean ageof the patients with malignant ovarian tumor is 52.33 ± 15.5 years. When the pathologic diagnosis reports examined it has been found that 34 of 55 patients (61.8 %) havehad epithelial type, 9 have had sex cord stromal tumor, 3 have had germ cell type and 9 of the patients have had metastatic ovarian cancer. Survival rates have been foundas 70.6 % for epithelial ovarian cancer, 100 % for sex cord stromal tumors, 100 % for germ cell tumor and 44.4 % for metastatic tumors. Despite the rapid development inexamination and imaging methods, histopathology is the pivotal issue in the diagnosis and also in sub-type diagnosis of pelvic mass lesions. The improvement is better inpatients evaluated and operated in gynecologic oncology centers. The two important factor in this subject is the experience of the surgeon for maximum salvage from thetumoral burden and the well examination by frozen section the immunohistochemical methods for the discrimination of gastrointestinal tumors which can mimic ovarianprimary tumors. Immunohistochemical methods have very important progression in diagnosis of cancer, its origin and subtypes and however IHC also could have a keyrole in treatment of cancer by targeted therapy.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Globocan (2012), Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018: https://gco.iarc.fr/
  • 2. T.C. Sağlık Bakanlığı. Türkiye Halk Sağlığı Genel Müdürlüğü. Kanser Dairesi Başkanlığı. Türkiye Kanser İstatistikleri: https://hsgm.saglik.gov.tr/ tr/kanser-istatistikleri
  • 3. National Cancer Institute: SEER Cancer Statistics Review (CSR) 1975– 2014. https://seer.cancer.gov/archive/csr/1975_2014/.
  • 4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30.
  • 5. Goodman MT, Shvetsov YB. ‘ Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United states, 1995-2004’. Cancer epidemiol Biomarkers Prev. 2009;18:132-9.
  • 6. Vencken PM, Kriege M, Hoogwerf D, et al. ‘Chemosensitivity and outcome of BRCA1 and BRCA2 associated ovarian cancer patients after first line chemotherapy compared with sporadic ovarian cancer patients’ Ann Oncol. 2011;22:1346-52.
  • 7. Purdie DM, Bain CJ, siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104:228-32.
  • 8. Berek SJ, Berek and Novak’s Gynecology. 2007. p. 1457-9.
  • 9. Seidman JD, Russel P, Kurman RJ (2002). Surface epithelial tumours of the ovary. In: Kurman RJ (edn): Blaustein’s Pathology of the female genital tract, (5 th edn), Springer-Verlag, New York.
  • 10. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory, Am J surg Pathol. 2010;34:433-43.
  • 11. Chen VW, ruiz B, Kılleen JL, et al. Pathology and classification of ovarian tumors. Cancer. 2003;15(10 suppl):2631-42.
  • 12. Schumer ST, Cannistra SA. ‘Granulosa cell tumor of the ovary’,J clin Oncol. 2003;21:1180-9.
  • 13. Talerman A, Path FRC.(2002), Germ cell tumors of the ovary. In Kurman R (ed): Blaustein’ s Pathology of the Female Genital Tract, 5 th ed. New York, Springer-Verlag, p. 967-1034.
  • 14. Turan T, Aykan B, Koç S, et al. Analysis of metastatic ovarian tumors from extra-genital primary site. Tumori. 2006;92:493-7.
  • 15. Moore RG, Chung M, Granai GO, et al. Incidence of metastasis to the ovaries from nongenital tract tumors. Gynecol Oncol. 2004;93: 87-91.
  • 16. Ümmugul Ü, Arslan ŞH, et al. Isolated ovarian metastasis of gastric cancer. Krukenberg Tumor Contemp Oncol (Pozn). 2013;17:515-9.
  • 17. Asotra S, Sharma J, Sharma N. Metastatic ovarian tumor. J Cytol. 2009;26:144-5.
  • 18. Di Saia, Creasman. Clinical Gynecologic Oncology 8th Ed. 2012;Chapter 12, p. 354. Elsevier Saunders
  • 19. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology. 2005; 47:231-247.
  • 20. Kriplani D, Patel MM. Immunohistochemistry: a diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary. South Asian J Cancer. 2013;2:254-8.
  • 21. Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with β-catenin. Histopathology. 2003;43:151-6.
  • 22. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913-9.
  • 23. Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6:252.
  • 24. Nonaka D, Chiriboga L, soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J surg Pathol. 2008;32:1566-71.
  • 25. Ren S, Klump W. Gynecologic serous carcinoma An Immunohistochemical analysis of malignant body fluid specimens. Arch Pathol Lab Med. 2019;143:677-82.
  • 26. Berezowski K, Stastny JF, Kornstein MJ Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-9.
  • 27. McCluggage WG, Maxwell P Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001;38:403-8.
  • 28. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG Ovarian sex cordstromal tumors: An immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584-90.
  • 29. Ordóñez NG The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol. 2006;19:417-28.
  • 30. Mouhamed HA. The diagnostic utility of immunohistochemistry in undifferentiated ovarian carcinoma. Arch Cancer Res. 2017;5:143.
  • 31. Bahrami A, Truong LD, Ro JY. Undifferentiated tumor: True identity by immunohistochemistry. Arch Pathol Lab Med. 2008;132:326-48.
  • 32. Goel A, Rao NM, Santhi V, Byna SS, Grandhi B, Conjeevaram J. Immunohistochemical characterization of normal ovary and common epithelial ovarian neoplasm with a monoclonal antibody to cytokeratin and vimentin. Iran J Pathol. 2018;13:23-29.
  • 33. Hart WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathology International 2005;55:231-243.
  • 34. Carter JH, Deddens JA, Mueller G, et al. Transcription factors WT1and p53 combined: a prognostic biomarker in ovarian cancer. Br J Cancer. 2018;119:462–70.
  • 35. Liliac L, Carcangiu ML, Canevari S, et al. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. Rom J Morphol Embryol. 2013;54:17- 27.
  • 36. Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and prognostic significance of Ki-67 immunohistochemical expression in surface epithelial ovarian carcinoma. J Clin Diagn Res J Clin Diagn Res. 2017;11:8-12.
  • 37. Manu V, Hein TA, Boruah D, et al. Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. Med J Armed Forces India. 2020;76:30-6.
  • 38. Vassilev LT, Vu BT, Graves B, et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science. 2004;303:844–8.
  • 39. Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a spesific marker for ovarian clear cell adenocarcinoma. Modern Pathol. 2015;28:111-7.
  • 40. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinoma of the ovaries: incidence in routine practice with a new approch to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985- 93.
APA Baloglu D, INCI COSKUN E, Alan S, Yilmaz E, kutlutürk k (2020). Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. , 496 - 502. 10.5455/medscience.2020.09.9254
Chicago Baloglu Demet,INCI COSKUN EBRU,Alan Saadet,Yilmaz Ercan,kutlutürk koray Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. (2020): 496 - 502. 10.5455/medscience.2020.09.9254
MLA Baloglu Demet,INCI COSKUN EBRU,Alan Saadet,Yilmaz Ercan,kutlutürk koray Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. , 2020, ss.496 - 502. 10.5455/medscience.2020.09.9254
AMA Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. . 2020; 496 - 502. 10.5455/medscience.2020.09.9254
Vancouver Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. . 2020; 496 - 502. 10.5455/medscience.2020.09.9254
IEEE Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k "Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance." , ss.496 - 502, 2020. 10.5455/medscience.2020.09.9254
ISNAD Baloglu, Demet vd. "Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance". (2020), 496-502. https://doi.org/10.5455/medscience.2020.09.9254
APA Baloglu D, INCI COSKUN E, Alan S, Yilmaz E, kutlutürk k (2020). Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science, 9(2), 496 - 502. 10.5455/medscience.2020.09.9254
Chicago Baloglu Demet,INCI COSKUN EBRU,Alan Saadet,Yilmaz Ercan,kutlutürk koray Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science 9, no.2 (2020): 496 - 502. 10.5455/medscience.2020.09.9254
MLA Baloglu Demet,INCI COSKUN EBRU,Alan Saadet,Yilmaz Ercan,kutlutürk koray Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science, vol.9, no.2, 2020, ss.496 - 502. 10.5455/medscience.2020.09.9254
AMA Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science. 2020; 9(2): 496 - 502. 10.5455/medscience.2020.09.9254
Vancouver Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance. Medicine Science. 2020; 9(2): 496 - 502. 10.5455/medscience.2020.09.9254
IEEE Baloglu D,INCI COSKUN E,Alan S,Yilmaz E,kutlutürk k "Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance." Medicine Science, 9, ss.496 - 502, 2020. 10.5455/medscience.2020.09.9254
ISNAD Baloglu, Demet vd. "Immunohistochemical profile in malignant ovarian tumors operated in our center and its discriminative importance". Medicine Science 9/2 (2020), 496-502. https://doi.org/10.5455/medscience.2020.09.9254